173 related articles for article (PubMed ID: 28054140)
41. Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?
Somervaille TC; Cleary ML
Int J Hematol; 2010 Jun; 91(5):735-41. PubMed ID: 20454944
[TBL] [Abstract][Full Text] [Related]
42. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in
Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA
J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231
[TBL] [Abstract][Full Text] [Related]
43. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
[TBL] [Abstract][Full Text] [Related]
44. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
45. Meis1 maintains stemness signature in MLL-AF9 leukemia.
Kumar AR; Sarver AL; Wu B; Kersey JH
Blood; 2010 Apr; 115(17):3642-3. PubMed ID: 20430967
[No Abstract] [Full Text] [Related]
46. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
47. c-Met inhibition in a HOXA9/Meis1 model of CN-AML.
Mulgrew NM; Kettyle LM; Ramsey JM; Cull S; Smyth LJ; Mervyn DM; Bijl JJ; Thompson A
Dev Dyn; 2014 Jan; 243(1):172-81. PubMed ID: 24307265
[TBL] [Abstract][Full Text] [Related]
48. Therapy-related acute myeloid leukemia 6 years after clonal detection of inv(11)(q21q23) and MLL gene rearrangement.
Takei N; Suzukawa K; Mukai HY; Itoh T; Okoshi Y; Yoda Y; Nagasawa T
Int J Hematol; 2006 Apr; 83(3):247-51. PubMed ID: 16720556
[TBL] [Abstract][Full Text] [Related]
49. Targeting the undruggable: menin inhibitors ante portas.
Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
[TBL] [Abstract][Full Text] [Related]
50. A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.
Hassan JJ; Lieske A; Dörpmund N; Klatt D; Hoffmann D; Kleppa MJ; Kustikova OS; Stahlhut M; Schwarzer A; Schambach A; Maetzig T
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502319
[No Abstract] [Full Text] [Related]
51. Transcription factor AP-2α regulates acute myeloid leukemia cell proliferation by influencing Hoxa gene expression.
Ding X; Yang Z; Zhou F; Wang F; Li X; Chen C; Li X; Hu X; Xiang S; Zhang J
Int J Biochem Cell Biol; 2013 Aug; 45(8):1647-56. PubMed ID: 23660297
[TBL] [Abstract][Full Text] [Related]
52. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.
Matsuo H; Yoshida K; Nakatani K; Harata Y; Higashitani M; Ito Y; Kamikubo Y; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Miyano S; Meggendorfer M; Haferlach C; Ogawa S; Adachi S
Blood Adv; 2020 Oct; 4(19):4623-4631. PubMed ID: 32991719
[TBL] [Abstract][Full Text] [Related]
53. MOZ is critical for the development of MOZ/MLL fusion-induced leukemia through regulation of Hoxa9/Meis1 expression.
Katsumoto T; Ogawara Y; Yamagata K; Aikawa Y; Goitsuka R; Nakamura T; Kitabayashi I
Blood Adv; 2022 Oct; 6(19):5527-5537. PubMed ID: 35947126
[TBL] [Abstract][Full Text] [Related]
54.
Fu JF; Shih LY; Yen TH
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34080665
[TBL] [Abstract][Full Text] [Related]
55. Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report.
Naghashpour M; Lancet J; Moscinski L; Zhang L
Am J Hematol; 2010 Jun; 85(6):451-4. PubMed ID: 20513125
[TBL] [Abstract][Full Text] [Related]
56. Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia.
Zhao L; Zhang P; Galbo PM; Zhou X; Aryal S; Qiu S; Zhang H; Zhou Y; Li C; Zheng D; Bhatia R; Lu R
Blood Adv; 2021 Nov; 5(22):4727-4740. PubMed ID: 34597364
[TBL] [Abstract][Full Text] [Related]
57. Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia.
Zeisig BB; Fung TK; Zarowiecki M; Tsai CT; Luo H; Stanojevic B; Lynn C; Leung AYH; Zuna J; Zaliova M; Bornhauser M; von Bonin M; Lenhard B; Huang S; Mufti GJ; So CWE
Sci Transl Med; 2021 Feb; 13(582):. PubMed ID: 33627486
[TBL] [Abstract][Full Text] [Related]
58. Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
Peng L; Tang Y; Zhang Y; Guo S; Peng L; Ye L; Wang Y; Jiang Y
Leuk Lymphoma; 2018 Oct; 59(10):2423-2430. PubMed ID: 29043883
[TBL] [Abstract][Full Text] [Related]
59. The Historical Relationship Between Meis1 and Leukemia.
Meriç N; Kocabaş F
Adv Exp Med Biol; 2022; 1387():127-144. PubMed ID: 35304708
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia.
Xu X; Schneider B
Cell Oncol (Dordr); 2019 Apr; 42(2):117-130. PubMed ID: 30446944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
